with moderate-to-severe atopic dermatitis for an initial treatment phase of 16 weeks. Patients who responded to treatment (defined as patients who achieved an investigator’s global assessment score of ...

"I was first diagnosed I think I was 11 or 12."That was devastating for Scott Hedgpeth who has always loved being active and ...

When conventional treatments for moderate to severe atopic dermatitis become less effective, targeted therapies may help.

While eczema and dermatitis typically cause skin discoloration ... or the condition is not responding to over-the-counter treatments, you may have a skin infection or an underlying condition.

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis ...

Minghui has reported positive topline outcomes from the Phase III trial of MH004 for treating mild to moderate atopic ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...